Skip to main content

Professional Activities

Conference Roles

  • The application of nanotechnology for optimisation of antiretroviral drug delivery, by Invitation (CLINAM, 2014)
  • Sustained Release Formulations for HIV Therapy, by Invitation (American Society for Nanomedicine, 2014)
  • Improved Oral Delivery of Antiretroviral Drugs Via A Novel Synthesis of Solid Drug Nanoparticle Form, by Invitation (British Society For Nanomedicine / SelectBio, 2014)
  • A flexible and scalable alternative to nanomilling for formation of solid drug nanoparticles, by Invitation (NIH/DAIDS, 2014)
  • Iterating synthesis with pharmacology to accelerate nanomedicine development, by Invitation (British Pharmacological Society, 2013)
  • How to Target HIV with Nanomedicine, by Invitation (European AIDS Society, 2013)
  • Improved pharmacokinetics of antiretroviral drugs through formation of solid drug nanoparticles, by Invitation (Pharmacokinetics UK, 2013)
  • Emerging technologies and challenges for development of long acting therapies, by Invitation (NIH/NIAID/DHHS, 2013)
  • The role of drug transporters in pharmacokinetics, DDIs and safety of antiretrovirals, by Invitation (Merck, 2013)
  • The importance of studying drug transporters in HCV drug development, by Invitation (HCV Drug Development Advisory Group, 2013)
  • The impact of hepatic transporters and pharmacogenetics on the pharmacokinetics of anti-HCV drugs, by Invitation (The International Liver Congress, 2013)
  • What potential role will novel oral formulations (nanoformulations and nanotechnology) play in HIV, by Invitation (CADO2, 2013)
  • Nanomedicine in HIV: which perspectives?, by Invitation (University of Turin, 2013)
  • Recent advances in pharmacogenetics of antiretroviral therapy, by Invitation (University of Belgrade, Belgrade, Serbia, 2012)
  • Pharmacological assessment of antiretroviral solid drug nanoparticles, by Invitation (Herriot Watt University, Edinburgh, UK, 2012)
  • Application of solid drug nanoparticles to treatment of Human Immunodeficiency Virus infection, by Invitation (New frontiers: Inaugural meeting of the British Society for Nanomedicine, the Athenaeum, Liverpool, UK, 2012)
  • Little Big Medicine, by Invitation (International Society on Thrombosis and Haemostasis (ISTH) conference, BT Convention Centre, Liverpool, UK, 2012)
  • The role of influx and efflux transporters in pharmacokinetics, distribution and safety of antiretro, by Invitation (Merck Global Therapeutics Expert forum, Philadelphia, USA, 2012)
  • Nanotechnology and Medicine, by Invitation (Liverpool Life Sciences Network - Spring Networking Event, Hard Days Night Hotel, Liverpool, UK, 2012)
  • Integrated Early Assessment of Nano-particle Risks and Benefits , by Invitation (4th Georgia Symposium on Nanotechnology and Infectious Diseases, Atlanta, USA, 2012)
  • Use of nanomaterials in drug delivery systems, by Invitation (Modular Training Programme in Applied Toxicology, Nanotoxicology, University of Surrey, Guilford, UK, 2011)
  • How can we solve the problem of second – line HIV and TB drug interactions?, by Invitation (Médecins Sans Frontières Campaign for Access to Essential Medicines – ART Sequencing Workshop, Geneva, Switzerland, 2011)
  • Insight into the Pharmacogenetics of Clinically Important Drug Transporters, by Invitation (World Drug Transporter Summit, Boston, USA, 2011)
  • Pharmacogenomics and Antimicrobial Agents, by Invitation (29th Annual meeting of the European Society for Paediatric Infectious Diseases, The Hague, Netherlands, 2011)
  • Non-attrition nanoparticles for delivery of antiretroviral drugs, by Invitation (University of Nebraska Medical Centre, Omaha, USA, 2011)
  • The application of nanotechnology to improve bioavailability of antiretroviral drugs, by Invitation (12th International Workshop on Clinical Pharmacology of HIV Therapy, Miami, Florida, USA, 2011)
  • Pharmacogenomics, by Invitation (6th Residential Course on Clinical Pharmacology of Antiretrovirals, Torino, Italy. , 2011)
  • Pharmacogenetic determinants of response to therapy of HIV infection., by Invitation (Molecular Diagnostics 2010, Moscow, Russia, 2010)
  • Nanoparticles for oral antiretroviral drug delivery: balancing efficacy and safety., by Invitation (The DAIDS Workshop: Nano & Emerging Technologies for HIV, 2010)
  • The Impact of Pharmacogenetics on Variability in Drug Disposition., by Invitation (Department of Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, USA, 2010)
  • HIV drug disposition: a pharmacogenetic perspective, by Invitation (Harvard School of Public Health, Program for HIV Prevention and Treatment, Chiang Mai, Thailand, 2010)
  • Transporter pharmacogenetics - from bench to bedside and back again, by Invitation (DMDG Open Meeting, University of Kent, Canterbury, UK, 2010)
  • Using Transporter Pharmacogenetics to Improve Patient Care., by Invitation (Clinically Relevant Drug Transporters, CCT Venues Canary Wharf, London UK, 2010)
  • Nanoparticle Delivery of Antiretroviral Drugs: Opportunities and Safety Concerns., by Invitation (School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK., 2010)
  • Pharmacogenetics – Upcoming Applications to Patient Care. , by Invitation (17th Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco, USA., 2010)
  • HIV therapy- New Insights in Pharmacogenetics and Pharmokinetics, by Invitation (Klinik I für Inneren Medizin, Cologne, Germany, 2009)
  • Nanotechnology-based medicinal products for human use-current issues and future developments., by Invitation (British Toxicology Society Autumn meeting. , 2009)
  • Pharmacogenetics and pharmacogenomics. , by Invitation (4th Residential Course on Clinical Pharmacology of Antiretrovirals, Torino, Italy. , 2009)
  • Investigating the mechanisms of variability in antiretroviral pharmacokinetics., by Invitation (Ottawa Health Research Institute, Ottawa, Ontario, Canada., 2008)
  • Inter-individual variability in drug disposition, by Invitation (AstraZeneca R&D Charnwood, 2008)
  • Pharmacogenetics and antiretrovirals: an African Perspective. , by Invitation (UK-Ghana Royal Society HIV workshop, 2008)
  • Pharmacogenetics and pharmacogenomics, by Invitation (3rd Residential Course on Clinical Pharmacology of Antiretrovirals, Torino, Italy, 2007)
  • HIV Pharmacology, by Invitation (Liverpool School of Tropical Medicine, 2007)
  • Pharmocogenomics, by Invitation (British Association for Sexual Health and HIV spotlight meeting, London, UK. , 2007)
  • The role of nuclear receptors in drug metabolism and disposition., by Invitation (School of Biomedical Sciences, University of Ulster, Coleraine campus, Cromore Road, Coleraine, Co. Londonderry., 2007)
  • Pharmacogenetics of HIV therapy., by Invitation (Abbott symposium at the BHIVA spring meeting, London, UK., 2007)
  • Host factors influencing variability in response to antiretroviral drugs., by Invitation (Shenyang Pharmaceutical University, LiaoNing, P.R.China., 2006)
  • Host Determinants of Antiretroviral Treatment Response., by Invitation (Molecular and Biochemical Parasitology Research Retreat, Whinfell Forest, UK., 2006)
  • Induction of Intestinal and Hepatic Disposition Genes by Paradigm Nuclear Receptor Ligands, by Invitation (AstraZeneca R&D Charnwood, Loughborough, Leics, UK, 2005)
  • Pharmacogenetics of Drug Transport / Metabolism in HIV therapy, by Invitation (South West Clinical Pharmacology Meeting, Southampton, UK, 2004)
  • Relationship between drug transporters and chemokine receptors: relevance to UK-427, 857, by Invitation (Pfizer central Research, Sandwich, Kent, UK, 2004)
  • In vitro interaction between mefloquine and saquinavir: The role of breast cancer resistance protein, by Invitation (5th Colloquium of the University of Liverpool Centre for Comparative Infectious Diseases, Liverpool, UK, 2004)
  • The reciprocal role of transporters and chemokine receptors on drug response, by Invitation (College of Pharmacy, Duluth, University of Minnesota, Minneapolis, MN, USA, 2003)
  • The reciprocal role of transporters and chemokine receptors on drug response, by Invitation (Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA, 2003)

Editorships

  • British Journal of Pharmacology (Guest Editor , 2013 - 2014)
  • Nanomedicine: Nanotechnology, Biology and Medicine (Editorial Board, 2012 - present)
  • Frontiers in Pharmacogenetics and Pharmacogenomics (Review Editor, 2010 - present)

Examination Roles

  • University of Newcastle upon Tyne, PhD (2012)
  • University of Surrey, PhD (2011)

Organisations I have been associated with

  • Presentation to local school students and staff (2012 - present)
  • Presentation to local business representatives (2012 - present)
  • British Society for Nanomedicine (2012 - present)

Professional Body Memberships

  • British Society of Nanomedicine (Chair-Elect, 2012 - present)
  • Society of Biology (Member, 2012 - present)
  • British HIV Association (Member, 2007 - present)
  • British Pharmacological Society (Member, 2005 - present)
  • International Society for the Study of Xenobiotics (Member, 2003 - present)

Other Administrative or Committee Roles

  • Professor Owen is Chair of the British Society for Nanomedicine (www.BritishSocietyNanomedicine.org), a member of several committees within the University and is the manager of the Departmental Containment Level III facility.